Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry

Joo Yong Hahn, Young Bin Song, Jin Ho Choi, Sung Hyuk Choi, Sung Yun Lee, Hun Sik Park, Seung Ho Hur, Sahng Lee, Kyoo Rok Han, Seung-Woon Rha, Byung Ryul Cho, Jong Sun Park, Junghan Yoon, Do-Sun Lim, Sang Hoon Lee, Hyeon Cheol Gwon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48-1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients.

Original languageEnglish
Pages (from-to)2314-2321
Number of pages8
JournalCirculation Journal
Volume74
Issue number11
DOIs
Publication statusPublished - 2010 Nov 1

Fingerprint

Stents
Registries
clopidogrel
Myocardial Infarction
Therapeutics
Thrombosis
Aspirin
zotarolimus
Propensity Score
Drug-Eluting Stents
Cardiogenic Shock
Left Ventricular Dysfunction
Transplants

Keywords

  • Antiplatelets
  • Drug-eluting stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents : The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry. / Hahn, Joo Yong; Song, Young Bin; Choi, Jin Ho; Choi, Sung Hyuk; Lee, Sung Yun; Park, Hun Sik; Hur, Seung Ho; Lee, Sahng; Han, Kyoo Rok; Rha, Seung-Woon; Cho, Byung Ryul; Park, Jong Sun; Yoon, Junghan; Lim, Do-Sun; Lee, Sang Hoon; Gwon, Hyeon Cheol.

In: Circulation Journal, Vol. 74, No. 11, 01.11.2010, p. 2314-2321.

Research output: Contribution to journalArticle

Hahn, JY, Song, YB, Choi, JH, Choi, SH, Lee, SY, Park, HS, Hur, SH, Lee, S, Han, KR, Rha, S-W, Cho, BR, Park, JS, Yoon, J, Lim, D-S, Lee, SH & Gwon, HC 2010, 'Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry', Circulation Journal, vol. 74, no. 11, pp. 2314-2321. https://doi.org/10.1253/circj.CJ-10-0347
Hahn, Joo Yong ; Song, Young Bin ; Choi, Jin Ho ; Choi, Sung Hyuk ; Lee, Sung Yun ; Park, Hun Sik ; Hur, Seung Ho ; Lee, Sahng ; Han, Kyoo Rok ; Rha, Seung-Woon ; Cho, Byung Ryul ; Park, Jong Sun ; Yoon, Junghan ; Lim, Do-Sun ; Lee, Sang Hoon ; Gwon, Hyeon Cheol. / Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents : The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry. In: Circulation Journal. 2010 ; Vol. 74, No. 11. pp. 2314-2321.
@article{33563919fca14a0b89841ae163ae7bad,
title = "Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry",
abstract = "Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4{\%}) had cardiac deaths, 3 patients (0.4{\%}) had MI, and 4 patients (0.5{\%}) had definite or probable ST, leading to the primary outcome in 5 patients (0.6{\%}). Death, MI, or any revascularization occurred in 68 patients (8.3{\%}). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95{\%}CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95{\%}CI, 0.48-1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients.",
keywords = "Antiplatelets, Drug-eluting stents",
author = "Hahn, {Joo Yong} and Song, {Young Bin} and Choi, {Jin Ho} and Choi, {Sung Hyuk} and Lee, {Sung Yun} and Park, {Hun Sik} and Hur, {Seung Ho} and Sahng Lee and Han, {Kyoo Rok} and Seung-Woon Rha and Cho, {Byung Ryul} and Park, {Jong Sun} and Junghan Yoon and Do-Sun Lim and Lee, {Sang Hoon} and Gwon, {Hyeon Cheol}",
year = "2010",
month = "11",
day = "1",
doi = "10.1253/circj.CJ-10-0347",
language = "English",
volume = "74",
pages = "2314--2321",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "11",

}

TY - JOUR

T1 - Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents

T2 - The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry

AU - Hahn, Joo Yong

AU - Song, Young Bin

AU - Choi, Jin Ho

AU - Choi, Sung Hyuk

AU - Lee, Sung Yun

AU - Park, Hun Sik

AU - Hur, Seung Ho

AU - Lee, Sahng

AU - Han, Kyoo Rok

AU - Rha, Seung-Woon

AU - Cho, Byung Ryul

AU - Park, Jong Sun

AU - Yoon, Junghan

AU - Lim, Do-Sun

AU - Lee, Sang Hoon

AU - Gwon, Hyeon Cheol

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48-1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients.

AB - Background: The optimal duration of dual antiplatelet therapy remains controversial. Methods and Results: Between December 2006 and March 2008, 823 patients were enrolled in a prospective multicenter registry for 3-month dual antiplatelet therapy (aspirin 100-200 mg+clopidogrel 75 mg daily) followed by aspirin mono-therapy after zotarolimus-eluting stents (ZES). Major exclusion criteria were: cardiogenic shock, stent thrombosis (ST)-segment elevation myocardial infarction (MI) within 48 h, previous drug-eluting stent implantation, severe left ventricular dysfunction, bifurcation lesions requiring 2-stenting, left main and graft lesions. The primary outcome was a composite of cardiac death, MI, or ST at 1 year. The median duration of dual antiplatelet therapy was 95 days (interquartile range 90-101). At 1 year, 3 patients (0.4%) had cardiac deaths, 3 patients (0.4%) had MI, and 4 patients (0.5%) had definite or probable ST, leading to the primary outcome in 5 patients (0.6%). Death, MI, or any revascularization occurred in 68 patients (8.3%). Among patients who were event-free at 3 months (n=812), clopidogrel was discontinued at 3 months in 661 patients and was continued for longer than 3 months in 151 patients. Discontinuation of clopidogrel at 3 months did not increase the primary outcome (HR 0.90; 95%CI, 0.09-9.02), death, MI, or any revascularization (HR 0.89; 95%CI, 0.48-1.67) after adjustment for the propensity score. Conclusions: Three-month dual antiplatelet therapy seems to be feasible after ZES implantation in relatively low-risk patients.

KW - Antiplatelets

KW - Drug-eluting stents

UR - http://www.scopus.com/inward/record.url?scp=78349250911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349250911&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-10-0347

DO - 10.1253/circj.CJ-10-0347

M3 - Article

C2 - 20938098

AN - SCOPUS:78349250911

VL - 74

SP - 2314

EP - 2321

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 11

ER -